G0326000
Gliclazide
European Pharmacopoeia (EP) Reference Standard
Manufacturer: Sigma Aldrich
CAS Number: 21187-98-4
Synonym(S): 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 20 MG | G0326000-20-MG | In Stock | ₹ 15,966.88 |
G0326000 - 20 MG
In Stock
Quantity
1
Base Price: ₹ 15,966.88
GST (18%): ₹ 2,874.038
Total Price: ₹ 18,840.918
grade
pharmaceutical primary standard
API family
gliclazide
manufacturer/tradename
EDQM
mp
163-169 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
InChI
1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
InChI key
BOVGTQGAOIONJV-UHFFFAOYSA-N
Other Options
| Image | Product Name | Manufacturer | Price Range | |
|---|---|---|---|---|
Sigma Aldrich Fine Chemicals Biosciences Gliclazide British Pharmacopoeia (BP) Reference Standard | 21187-98-4 | MFCD00409893 | | -- | ₹ 29,982.32 | ||
Sigma Aldrich Fine Chemicals Biosciences Gliclazide European Pharmacopoeia (EP) Reference Standard | 21187-98-4 | MFCD00409893 | | -- | ₹ 24,531.07 | ||
Sigma Aldrich Fine Chemicals Biosciences Gliclazide powder, >=98% | 21187-98-4 | MFCD00409893 | 5G | -- | ₹ 17,662.05 | ||
Gliclazide | -- | ₹ 25,070.70 | ||
21187-98-4 | 1-[(4-methylbenzene)sulfonyl]-3-{octahydrocyclopenta[c]pyrrol-2-yl}urea | -- | ₹ 890.00 - ₹ 29,815.00 |
Related Products
Description
- General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
- Application: Used in the treatment of non-insulin dependent diabetes mellitus (NIDDM).
- Biochem/physiol Actions: Oxidative modification of low-density lipoprotein (LDL) plays an important role in vascular dysfunction associated with diabetes mellitus. Gliclazide is a second-generation sulfonylurea with free-radical-scavenging activity. Incubation of human aortic smooth muscle cell (HASMC) with native human LDL (100 μg/mL) in the presence of increasing concentrations of gliclazide (1 to 10 μg/mL) resulted in a dose-dependent decrease in HASMC-mediated LDL oxidation. Exposure of HASMCs to gliclazide (1 to 10 μg/mL) and native LDL (100 μg/mL) also led to a dose-dependent decrease in oxidized LDL-induced human monocyte adhesion to HASMCs. In addition, incubation of HASMCs with gliclazide dramatically reduced the ability of oxidized LDL to stimulate the proliferation of these cells. Finally, treatment of HASMCs with gliclazide resulted in a marked decrease in oxidatively modified LDL-induced monocyte chemoattractant protein (MCP)-1 and human heat shock protein 70 (HSP 70) expression, both at the gene and protein levels. These results show that gliclazide, at concentrations in the therapeutic range (5 to 10 μg/mL), is effective in vitro in reducing vascular smooth muscle cell (VSMC) dysfunction induced by oxidatively modified LDL. Administration of gliclazide to type 2 diabetic patients could form part of the strategy for the prevention and management of diabetic cardiovascular diseases
- Packaging: The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
- Other Notes: Sales restrictions may apply.
SAFETY INFORMATION
Pictograms
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable